Last reviewed · How we verify
GSK investigational vaccine GSK1557482A
GSK investigational vaccine GSK1557482A is a Therapeutic vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Investigational indication under phase 3 evaluation (specific indication not publicly confirmed).
GSK1557482A is an investigational therapeutic vaccine designed to stimulate immune responses against specific tumor-associated antigens or pathogens.
GSK1557482A is an investigational therapeutic vaccine designed to stimulate immune responses against specific tumor-associated antigens or pathogens. Used for Investigational indication under phase 3 evaluation (specific indication not publicly confirmed).
At a glance
| Generic name | GSK investigational vaccine GSK1557482A |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Therapeutic vaccine |
| Modality | Biologic |
| Therapeutic area | Oncology or Immunology |
| Phase | Phase 3 |
Mechanism of action
As a vaccine candidate, GSK1557482A likely works by priming the adaptive immune system to recognize and attack cells expressing target antigens. The vaccine formulation may include adjuvants or delivery systems to enhance immunogenicity and promote both cellular and humoral immune responses.
Approved indications
- Investigational indication under phase 3 evaluation (specific indication not publicly confirmed)
Common side effects
- Injection site reactions
- Fever
- Fatigue
Key clinical trials
- Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children (PHASE3)
- Clinical Study in Children, 6 Months to 3 Years of Age, to Assess Two Dose Levels of an Experimental Flu Vaccine, Using a Licensed Influenza Virus Vaccine, Vaxigrip® as the Control (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK investigational vaccine GSK1557482A CI brief — competitive landscape report
- GSK investigational vaccine GSK1557482A updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about GSK investigational vaccine GSK1557482A
What is GSK investigational vaccine GSK1557482A?
How does GSK investigational vaccine GSK1557482A work?
What is GSK investigational vaccine GSK1557482A used for?
Who makes GSK investigational vaccine GSK1557482A?
What drug class is GSK investigational vaccine GSK1557482A in?
What development phase is GSK investigational vaccine GSK1557482A in?
What are the side effects of GSK investigational vaccine GSK1557482A?
Related
- Drug class: All Therapeutic vaccine drugs
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Oncology or Immunology
- Indication: Drugs for Investigational indication under phase 3 evaluation (specific indication not publicly confirmed)